Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment

IF 2.8 3区医学 Q2 INFECTIOUS DISEASES

HIV Medicine Pub Date : 2024-12-10 DOI:10.1111/hiv.13748

Kate Alford, Shiraaz Sidat, Katherine Bristowe, Paola Cicconi, Jamie H. Vera, Fiona Cresswell

{"title":"Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment","authors":"Kate Alford, Shiraaz Sidat, Katherine Bristowe, Paola Cicconi, Jamie H. Vera, Fiona Cresswell","doi":"10.1111/hiv.13748","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The twice-yearly, long-acting lenacapavir (LA LEN) antiretroviral therapy (ART), when combined with an optimised background regimen, provides a subcutaneous injectable treatment option for people with HIV. This study aimed to understand the preferences, barriers and facilitators for uptake and implementation of LA LEN, with a view to informing clinical implementation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In-depth qualitative interviews and focus groups with purposively sampled people with HIV and healthcare workers (HCWs) from UK HIV services were conducted. Transcripts were analysed using summative and conventional content analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty-four people with HIV with varied ART experience were recruited from two HIV services. Participants included 22 (65%) identifying as cisgender men and 12 (35%) identifying as cisgender women; median age was 55 years (range 26–76 years). Fourteen HIV HCWs took part in three focus groups. Four key themes and 12 subthemes were identified: LA LEN as a treatment option; LA LEN versus oral ART; switching considerations; and administration of LA LEN. The majority (88%) of people with HIV were interested in switching to LA LEN if offered. Preference was markedly reduced if an oral ART pairing was required. Convenience of the dosing schedule, reduced pill burden and issues around stigma were reasons for interest in LA LEN, but concerns regarding efficacy, dosing interval windows, monitoring and side effects were described. HCWs felt the benefit of LA LEN was as a treatment option for those with adherence issues, drug resistance and a high pill burden. Broader use of LA LEN raised concerns over drug resistance, delivery capacity and storage.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>LA LEN was viewed as a preferable treatment choice for many people with HIV, provided an all-injectable regimen was available. Feasibility assessments for provision of injectable ART and research on its potential for self-administration are needed.</p>\n </section>\n </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 3","pages":"441-450"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.13748","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.13748","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The twice-yearly, long-acting lenacapavir (LA LEN) antiretroviral therapy (ART), when combined with an optimised background regimen, provides a subcutaneous injectable treatment option for people with HIV. This study aimed to understand the preferences, barriers and facilitators for uptake and implementation of LA LEN, with a view to informing clinical implementation.

Methods

In-depth qualitative interviews and focus groups with purposively sampled people with HIV and healthcare workers (HCWs) from UK HIV services were conducted. Transcripts were analysed using summative and conventional content analysis.

Results

Thirty-four people with HIV with varied ART experience were recruited from two HIV services. Participants included 22 (65%) identifying as cisgender men and 12 (35%) identifying as cisgender women; median age was 55 years (range 26–76 years). Fourteen HIV HCWs took part in three focus groups. Four key themes and 12 subthemes were identified: LA LEN as a treatment option; LA LEN versus oral ART; switching considerations; and administration of LA LEN. The majority (88%) of people with HIV were interested in switching to LA LEN if offered. Preference was markedly reduced if an oral ART pairing was required. Convenience of the dosing schedule, reduced pill burden and issues around stigma were reasons for interest in LA LEN, but concerns regarding efficacy, dosing interval windows, monitoring and side effects were described. HCWs felt the benefit of LA LEN was as a treatment option for those with adherence issues, drug resistance and a high pill burden. Broader use of LA LEN raised concerns over drug resistance, delivery capacity and storage.

Conclusions

LA LEN was viewed as a preferable treatment choice for many people with HIV, provided an all-injectable regimen was available. Feasibility assessments for provision of injectable ART and research on its potential for self-administration are needed.

查看原文本刊更多论文

Lenacapavir：患者和医疗保健提供者的看法和每年两次注射HIV治疗的潜在作用。

背景：每年两次的长效lenacapavir （LA LEN）抗逆转录病毒治疗（ART）与优化的背景方案相结合，为艾滋病毒感染者提供了一种皮下注射治疗选择。本研究旨在了解LA LEN的偏好、障碍和促进因素，以期为临床实施提供信息。方法：对英国HIV服务机构的HIV感染者和医护人员（HCWs）进行深入的定性访谈和焦点小组调查。使用总结性和常规内容分析分析转录本。结果：从两家艾滋病毒服务机构招募了34名具有不同抗逆转录病毒治疗经历的艾滋病毒感染者。参与者包括22名（65%）自认为是顺性别的男性和12名（35%）自认为是顺性别的女性；中位年龄为55岁（范围26-76岁）。14名艾滋病毒医护人员参加了三个焦点小组。确定了4个关键主题和12个次级主题：LA LEN作为治疗方案；LA LEN与口腔艺术；切换注意事项;和LA LEN的管理。如果有机会，大多数（88%）艾滋病毒感染者有兴趣转到LA LEN。如果需要口服抗逆转录病毒治疗配对，偏好明显降低。给药计划的便利性、减轻药丸负担和耻辱感问题是对LA LEN感兴趣的原因，但对疗效、给药间隔窗口、监测和副作用的担忧也进行了描述。HCWs认为LA LEN的好处是作为那些有依从性问题，耐药性和高药丸负担的治疗选择。LA LEN的广泛使用引发了对耐药性、输送能力和储存的担忧。结论：如果提供全注射方案，LA LEN被认为是许多艾滋病毒感染者更好的治疗选择。需要对提供可注射的抗逆转录病毒药物进行可行性评估，并研究其自我给药的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HIV Medicine 医学-传染病学

CiteScore

5.10

自引率

10.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.